These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 16979433)

  • 1. Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
    Meredith RF; Knox SJ
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S15-22. PubMed ID: 16979433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma.
    Ghobrial I; Witzig T
    Oncology (Williston Park); 2004 May; 18(5):623-30; discussion 633-4, 637-8, 640. PubMed ID: 15209190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    Meredith RF
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S23-9. PubMed ID: 16979435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
    de Nully Brown P; Jurlander J; Lindén O; Hansen M
    Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
    Alcindor T; Witzig TE
    Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status].
    Emmanouilides C
    Rev Esp Med Nucl; 2006; 25(1):42-54. PubMed ID: 16540013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
    Schilder R; Molina A; Bartlett N; Witzig T; Gordon L; Murray J; Spies S; Wang H; Wiseman G; White C
    Cancer Biother Radiopharm; 2004 Aug; 19(4):478-81. PubMed ID: 15453962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.
    Witzig TE
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S91-5. PubMed ID: 11587375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Dillman RO
    Curr Hematol Rep; 2003 Jan; 2(1):30-7. PubMed ID: 12901152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
    Witzig TE
    Drugs Today (Barc); 2004 Feb; 40(2):111-9. PubMed ID: 15045033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Logistics of therapy with the ibritumomab tiuxetan regimen.
    Meredith RF
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S35-8. PubMed ID: 16979437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
    Gordon LI; Witzig TE; Wiseman GA; Flinn IW; Spies SS; Silverman DH; Emmanouilides C; Cripe L; Saleh M; Czuczman MS; Olejnik T; White CA; Grillo-López AJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):87-92. PubMed ID: 11842394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.
    Macklis RM
    Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
    Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
    J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Contribution of radioimmunotherapy to the treatment of lymphoma].
    Rizzo-Padoin N
    Ann Pharm Fr; 2008; 66(5-6):300-8. PubMed ID: 19061730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.
    Juweid ME
    J Nucl Med; 2002 Nov; 43(11):1507-29. PubMed ID: 12411555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
    Witzig TE
    Best Pract Res Clin Haematol; 2006; 19(4):655-68. PubMed ID: 16997175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.